Tumor hypoxia and its clinical significance

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F13%3A%230000445" target="_blank" >RIV/00209805:_____/13:#0000445 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.mzm.cz/fileadmin/user_upload/publikace/casopisy/fm_49_2_2013/fm-2-2013-abstract-08.pdf" target="_blank" >http://www.mzm.cz/fileadmin/user_upload/publikace/casopisy/fm_49_2_2013/fm-2-2013-abstract-08.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Tumor hypoxia and its clinical significance

Popis výsledku v původním jazyce

In the light of intense cancer research, the tumor microenvironment has become a matter of great interest as it can influence many different aspects of tumor progression including growth, metastatic potential and response to treatment. In that field, lowoxygen pressure (hypoxia), which evolves from uncontrollable growth and poor vasculature, plays a significant role. The main executer of tumor cell responses to hypoxia is a transcription factor HIF-1 (hypoxia-inducible factor 1), which triggers molecular adjustments helping cells to overcome those unfavorable conditions. It is also known that hypoxia renders cells resistant to treatment and in consequence affects patient outcome. This review focuses on HIF-1-dependent adaptations to insufficient oxygen delivery as well as describing clinical problems arising from hypoxia. Lastly, it highlights importance of targeted therapy aiming at hypoxic pathways.

Název v anglickém jazyce

Tumor hypoxia and its clinical significance

Popis výsledku anglicky

In the light of intense cancer research, the tumor microenvironment has become a matter of great interest as it can influence many different aspects of tumor progression including growth, metastatic potential and response to treatment. In that field, lowoxygen pressure (hypoxia), which evolves from uncontrollable growth and poor vasculature, plays a significant role. The main executer of tumor cell responses to hypoxia is a transcription factor HIF-1 (hypoxia-inducible factor 1), which triggers molecular adjustments helping cells to overcome those unfavorable conditions. It is also known that hypoxia renders cells resistant to treatment and in consequence affects patient outcome. This review focuses on HIF-1-dependent adaptations to insufficient oxygen delivery as well as describing clinical problems arising from hypoxia. Lastly, it highlights importance of targeted therapy aiming at hypoxic pathways.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/ED2.1.00%2F03.0101" target="_blank" >ED2.1.00/03.0101: Regionální centrum aplikované molekulární onkologie (RECAMO)</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Folia Mendeliana

ISSN

0085-0748

e-ISSN

—

Svazek periodika

49

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

69-73

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—